Worth reading
33Immaterial
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Improvement
Direction inferred from the company’s description.Scale
15
¥100 million (increase in the consolidated ordinary profit target)Wording
Conditional
How definitive the wording is.Items stated in the management plan
FormulatedWhat happened to the previous plan¥6 billion → Not disclosed
Key initiatives
01Deepening existing businesses
02Accelerating overseas expansion
03Expanding the manufacturing business
04Taking on new markets and business areas
05Be Unique: Becoming a leading company in milk and protein
06Be Global: Pioneering the future of food
07Be Loved, Be Lacto: Connecting smiles and shared aspirations
Plan assumptionsBased on information available as of the announcement date and certain assumptions. The figures may fluctuate significantly due to various factors, including future changes in the business environment.
Risks identified by the company
The forward-looking statements, including numerical forecasts, may fluctuate significantly due to various factors, including future changes in the business environment.
Reason for revision or withdrawal
Amid significant changes in the business environment, the business platform has steadily evolved through growth in the Life Science business segment and the expansion of the manufacturing business in Asia. The Company has redefined its field of business activities as “Global” and is shifting its policy to focus on capital efficiency and profitability, rather than limiting its focus to scale expansion such as growth in revenue and volume.
Ordinary Profit Target¥6 billion → ¥7.5 billion（25％）
| Item | Details |
|---|---|
| Plan name | Long-Term Vision “LACTO VISION 2032 Ver.2.0” |
| Plan period | Final year: fiscal year ending November 2032 (the starting year is not stated; the previous long-term vision was formulated in 2023) |
| Progress against the plan | Formulated |
| Ordinary Profit Target | ¥6 billion → ¥7.5 billion（25％） |
| Plan assumptions | Based on information available as of the announcement date and certain assumptions. The figures may fluctuate significantly due to various factors, including future changes in the business environment. |
| Key initiatives | Deepening existing businesses, Accelerating overseas expansion, Expanding the manufacturing business, Taking on new markets and business areas, Be Unique: Becoming a leading company in milk and protein, Be Global: Pioneering the future of food, Be Loved, Be Lacto: Connecting smiles and shared aspirations |
| Results under the previous plan | ¥6 billion → Not disclosed |
| Reason for revision or withdrawal | Amid significant changes in the business environment, the business platform has steadily evolved through growth in the Life Science business segment and the expansion of the manufacturing business in Asia. The Company has redefined its field of business activities as “Global” and is shifting its policy to focus on capital efficiency and profitability, rather than limiting its focus to scale expansion such as growth in revenue and volume. |
| Risks identified | The forward-looking statements, including numerical forecasts, may fluctuate significantly due to various factors, including future changes in the business environment. |
| Publication date | 14 July 2026 |
Items this document does not state (16)
Sales TargetOperating profit targetOperating profit margin targetNet income targetROE targetROIC targetPayout ratio / DOE policyTreasury share acquisition policyCost of capitalSelf-assessment of PBR and share priceTotal investment planInvestment amount by sectorSegment targetNon-financial targetsSize of the Target MarketDate of board resolution
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Amid significant changes in the business environment, the business platform has steadily evolved through growth in the Life Science business segment and the expansion of the manufacturing business in Asia. In addition, the Company has defined its field of business activities as “Global” and shifted its policy to focus not only on scale expansion but also on capital efficiency and profitability.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.